<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/198AB9BA-BA2C-44ED-8F70-00A1213F1B2B"><gtr:id>198AB9BA-BA2C-44ED-8F70-00A1213F1B2B</gtr:id><gtr:name>F2g Ltd</gtr:name><gtr:address><gtr:line1>LANKRO WAY , ECCLES</gtr:line1><gtr:city>MANCHESTER</gtr:city><gtr:postCode>M30 0LX</gtr:postCode><gtr:region>North West</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/198AB9BA-BA2C-44ED-8F70-00A1213F1B2B" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>198AB9BA-BA2C-44ED-8F70-00A1213F1B2B</gtr:id><gtr:name>F2g Ltd</gtr:name><gtr:address><gtr:line1>LANKRO WAY , ECCLES</gtr:line1><gtr:city>MANCHESTER</gtr:city><gtr:postCode>M30 0LX</gtr:postCode><gtr:region>North West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>1331296.0</gtr:offerGrant><gtr:projectCost>2218826.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/2729762E-033D-4349-88A6-0B64EC138080"><gtr:id>2729762E-033D-4349-88A6-0B64EC138080</gtr:id><gtr:firstName>mike</gtr:firstName><gtr:surname>birch</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=102005"><gtr:id>9201F3A9-678C-4CBB-B2B7-41C12E7CA548</gtr:id><gtr:title>Phase I oral safety assessment of a novel antifungal for systemic fungal infections</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Collaborative R&amp;D</gtr:grantCategory><gtr:grantReference>102005</gtr:grantReference><gtr:abstractText>Systemic fungal disease is a life threatening groups of infections caused by yeasts and moulds that affects people who have impaired immune systems. The numbers of patients are increasing and the current threatment options are limited to three types of antifungal drug. Often these drugs have severe side effects or can't be used with other medicines. F2G has identified a new type of antifungal that works through a different mechanism. It is highly potent against many of the moulds that cause these serious infections. This project aims to develop this new antifungal drug by testing its safety in man and how it interacts with other drugs. Following this project the drug can be tested in patients suffering from serious infection.</gtr:abstractText><gtr:fund><gtr:end>2016-10-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2014-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1331296</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">102005</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>